LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Nektar Therapeutics

Uždarymo kaina

0.69 2.99

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

0.64

Max

0.69

Pagrindiniai rodikliai

By Trading Economics

Pajamos

44M

7.3M

Pardavimai

5.1M

29M

Pelnas, tenkantis vienai akcijai

-0.24

Pelno marža

24.888

Darbuotojai

61

EBITDA

48M

17M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+623.53% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-07

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-35M

133M

Ankstesnė atidarymo kaina

-2.3

Ankstesnė uždarymo kaina

0.69

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Nektar Therapeutics Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-05-16 19:39; UTC

Pagrindinės rinkos jėgos

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

2025-05-16 23:18; UTC

Svarbiausios naujienos

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

2025-05-16 22:30; UTC

Svarbiausios naujienos

U.S. Loses Last Triple-A Credit Rating -- Update

2025-05-16 21:56; UTC

Rinkos pokalbiai

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

2025-05-16 21:56; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-05-16 21:54; UTC

Svarbiausios naujienos

U.S. Loses Last Triple-A Credit Rating -- WSJ

2025-05-16 21:22; UTC

Rinkos pokalbiai

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

2025-05-16 21:17; UTC

Rinkos pokalbiai

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

2025-05-16 21:17; UTC

Svarbiausios naujienos

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

2025-05-16 21:05; UTC

Rinkos pokalbiai

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

2025-05-16 20:55; UTC

Įsigijimai, susijungimai, perėmimai

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

2025-05-16 20:50; UTC

Rinkos pokalbiai
Uždarbis

Financial Services Roundup: Market Talk

2025-05-16 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-05-16 20:37; UTC

Svarbiausios naujienos

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

2025-05-16 20:33; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

2025-05-16 20:30; UTC

Įsigijimai, susijungimai, perėmimai

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

2025-05-16 20:18; UTC

Svarbiausios naujienos

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

2025-05-16 20:16; UTC

Svarbiausios naujienos

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

2025-05-16 20:15; UTC

Uždarbis

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

2025-05-16 20:11; UTC

Įsigijimai, susijungimai, perėmimai

Henry Schein: William K. Daniel Joins Board

2025-05-16 20:10; UTC

Įsigijimai, susijungimai, perėmimai

Henry Schein: Strategic Investment by KKR Completed

2025-05-16 20:05; UTC

Įsigijimai, susijungimai, perėmimai

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

2025-05-16 19:38; UTC

Rinkos pokalbiai

Oil Futures Post Second Straight Weekly Gain -- Market Talk

2025-05-16 19:07; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures End Week Lower -- Market Talk

2025-05-16 18:51; UTC

Svarbiausios naujienos

Early Read on Consumer Sentiment Falls to Second Lowest on Record -- 5th Update

2025-05-16 18:41; UTC

Įsigijimai, susijungimai, perėmimai

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

2025-05-16 18:37; UTC

Rinkos pokalbiai

Gold Futures End Week on Negative Note -- Market Talk

2025-05-16 18:35; UTC

Svarbiausios naujienos

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

2025-05-16 18:32; UTC

Svarbiausios naujienos

Trump Floats Plan to Impose New Tariff Rates; Stocks Hold Steady -- WSJ

2025-05-16 18:28; UTC

Rinkos pokalbiai

Weaker Dollar Seen as Helping Some Business to Avoid Price Increases -- Market Talk

Akcijų palyginimas

Kainos pokytis

Nektar Therapeutics Prognozė

Kainos tikslas

By TipRanks

623.53% į viršų

12 mėnesių prognozė

Vidutinis 4.92 USD  623.53%

Aukščiausias 7 USD

Žemiausias 2 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Nektar Therapeutics kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

8 ratings

6

Pirkti

1

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

0.5949 / 0.7406Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. The company serves its clients in the United States and internationally. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.